title: Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
abstract: Rasburicase is currently approved at a dosage of 0.15-0.2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of rasburicase for preventing or managing TLS in adults. We collected retrospective data for 11 adults with hematologic malignancies who received a single 6-mg dose of rasburicase. All patients received intravenous hydration with urinary alkalinization and allopurinol; however, due to adverse reactions, two patients received short courses of allopurinol. Only patients at high risk for TLS (e.g., large tumor burden, increasing uric acid concentration) or those with TLS received rasburicase. The single dose of rasburicase 6 mg resulted in a median 0.0773-mg/kg dose (range 0.0232-0.1361 mg/kg). The single 6-mg dose rapidly lowered uric acid concentrations in 10 of the 11 patients. The median uric acid concentration of 11.7 mg/dl (range 7.4-17.4 mg/dl) declined to 2.0 mg/dl (range 0.5-15.4 mg/dl) within a day after rasburicase administration (p=0.022). In these 10 patients, uric acid concentrations remained low despite subsequent chemotherapy, and none required additional rasburicase doses. The only patient who did not respond to the single 6-mg rasburicase dose was a morbidly obese man (259 kg, body mass index 87 kg/m2) who subsequently responded to an additional dose of rasburicase 12 mg. These results warrant further investigation of a single 6-mg dose of rasburicase in adults with TLS or at high-risk for developing TLS.
authors.affiliation: Department of Pharmacy Services, Medical University Hospital, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
authors.forename: Anne M
authors.initials: AM
authors.lastname: McDonnell
authors.forename: Kristi L
authors.initials: KL
authors.lastname: Lenz
authors.forename: Debra A
authors.initials: DA
authors.lastname: Frei-Lahr
authors.forename: John
authors.initials: J
authors.lastname: Hayslip
authors.forename: Philip D
authors.initials: PD
authors.lastname: Hall
mesh_terms: D000328:Adult; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006074:Gout Suppressants / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014503:Urate Oxidase / Q000008:administration & dosage / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
chemical_list: D006074:Gout Suppressants; C469709:rasburicase; D014527:Uric Acid; D003404:Creatinine; D014503:Urate Oxidase